GlassScriptPhysician profile
Dana M Mann
NPI 1972995314
$13,190.77
in general payments reported to CMS, 2019-2025
29 companies · $3,293 in 2025
The $3,293 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,133 · 2022: $2,094 · 2023: $2,547 · 2024: $3,124 · 2025: $3,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,839 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,839.48 |
| Education | $124.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,273.47 | 2021-2025 | Krystexxa, Enbrel, Otezla |
| Janssen Biotech, INC. | $1,669.08 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,530.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,118.27 | 2021-2025 | Orencia |
| Pfizer INC. | $931.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $905.33 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $784.13 | 2021-2025 | |
| Horizon Therapeutics Plc | $755.16 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $722.08 | 2021-2025 | Benlysta |
| Ucb, INC. | $701.40 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $387.00 | 2021-2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $364.76 | 2021-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $214.17 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $175.25 | 2022-2025 | Purified Cortrophin Gel |
| Sandoz INC. | $101.03 | 2023-2025 | Hyrimoz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $95.85 | 2021-2025 | Acthar |
| Organon LLC | $93.64 | 2021-2025 | Renflexis, Hadlima |
| Tersera Therapeutics LLC | $75.26 | 2023-2025 | Quzyttir |
| Fresenius Kabi USA, LLC | $54.64 | 2023 | Idacio |
| Radius Health, INC. | $44.54 | 2022-2024 | Tymlos |
| Sobi, INC | $38.14 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.39 | 2025 | |
| Celltrion USA INC. | $24.61 | 2023 | Yuflyma |
| Takeda Pharmaceuticals U.S.A., INC. | $23.31 | 2024 | Hyqvia |
| Genentech USA, INC. | $20.42 | 2023 | Actemra |
| Ultragenyx Pharmaceutical INC. | $17.54 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $16.99 | 2024 | Arcalyst |
| Invivyd INC | $14.89 | 2025 | Pemgarda |
| Ascend Therapeutics US, LLC | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.